http://www.renalandurologynews.com Latest articles from Renal and Urology News Prostate Specific Antigen (PSA) RUN Prostate Specific Antigen (PSA) News and review articles on prostate specific antigen (PSA). Prostate Specific Antigen (PSA) custserv@haymarketmedia.com no Saw palmetto remains the most common herbal treatment for men with LUTS. http://www.renalandurologynews.com/saw-palmetto-has-no-effect-on-psa/article/297230/ Mon, 17 Jun 2013 13:00:00 GMT Saw palmetto remains the most common herbal treatment for men with LUTS. RUN Dr. Crawford talks about a new epigenetic test that helps to prevent unnecessary biopsies in men with prostate cancer. http://www.renalandurologynews.com/e-david-crawford-md-the-benefits-of-confirmmdx/article/294846/ Fri, 24 May 2013 17:05:57 GMT Dr. Crawford talks about a new epigenetic test that helps to prevent unnecessary biopsies in men with prostate cancer. RUN Researchers say they have identified genetic variants that can increase PSA concentrations and prostate cancer risk. http://www.renalandurologynews.com/genetic-analyses-could-reduce-the-number-of-prostate-biopsies/article/291134/ Thu, 16 May 2013 13:00:00 GMT Researchers say they have identified genetic variants that can increase PSA concentrations and prostate cancer risk. RUN Shared decision-making about screening recommended for men aged 55-69 years. http://www.renalandurologynews.com/updated-prostate-cancer-screening-guidelines-announced/article/292385/ Tue, 07 May 2013 23:30:00 GMT Shared decision-making about screening recommended for men aged 55-69 years. RUN Median survival time from diagnosis improved by a median of 43 months from the pre-PSA to the post-PSA era. http://www.renalandurologynews.com/prostate-cancer-deaths-occurring-at-older-ages/article/292350/ Tue, 07 May 2013 21:00:00 GMT Median survival time from diagnosis improved by a median of 43 months from the pre-PSA to the post-PSA era. RUN Pathologic progression not more likely in patients who start active surveillance with a PSA of 10 ng/mL or higher, study finds. http://www.renalandurologynews.com/prostate-cancer-as-may-be-ok-despite-higher-psa/article/292042/ Sun, 05 May 2013 20:00:00 GMT Pathologic progression not more likely in patients who start active surveillance with a PSA of 10 ng/mL or higher, study finds. RUN Study reveals no significant association between BMI and prebiopsy PSA, Gleason score, clinical T stage, and D'Amico risk. http://www.renalandurologynews.com/prostate-cancer-severity-not-linked-to-obesity/article/290466/ Thu, 25 Apr 2013 13:36:26 GMT Study reveals no significant association between BMI and prebiopsy PSA, Gleason score, clinical T stage, and D'Amico risk. RUN New findings provide a rationale for immunotherapy as an early step in sequencing treatment algorithm for mCRPC. http://www.renalandurologynews.com/lower-psa-predicts-better-survival-in-sipuleucel-t-recipients/article/288588/ Fri, 12 Apr 2013 19:30:00 GMT New findings provide a rationale for immunotherapy as an early step in sequencing treatment algorithm for mCRPC. RUN New findings raise questions about PSA screening criteria. http://www.renalandurologynews.com/prostate-cancer-deaths-can-occur-despite-normal-initial-psa/article/284722/ Sat, 16 Mar 2013 18:00:00 GMT New findings raise questions about PSA screening criteria. RUN Stopping PSA testing at age 70 may be premature, at least in men with high-risk disease and long life expectancies, researchers conclude. http://www.renalandurologynews.com/prostate-cancer-benefit-lasts-up-to-nine-years-after-last-screening/article/284721/ Sat, 16 Mar 2013 14:00:00 GMT Stopping PSA testing at age 70 may be premature, at least in men with high-risk disease and long life expectancies, researchers conclude. RUN The survival benefit is limited to men aged 55-69 years at initial screening, large European study finds. http://www.renalandurologynews.com/psa-screening-lowers-prostate-cancer-death-risk/article/284717/ Sat, 16 Mar 2013 10:17:15 GMT The survival benefit is limited to men aged 55-69 years at initial screening, large European study finds. RUN PSA concentrations are higher in men who engage in more sedentary behavior and lower levels of light physical activity, a study found. http://www.renalandurologynews.com/psa-levels-higher-in-sedentary-men-study-finds/article/276361/ Thu, 17 Jan 2013 14:00:00 GMT PSA concentrations are higher in men who engage in more sedentary behavior and lower levels of light physical activity, a study found. RUN Researchers urge prostate biopsies for men with a low neutrophil count and increased serum PSA level. http://www.renalandurologynews.com/low-neutrophil-count-may-predict-prostate-cancer/article/270118/ Wed, 28 Nov 2012 10:10:23 GMT Researchers urge prostate biopsies for men with a low neutrophil count and increased serum PSA level. RUN The estimated seven-year cumulative rates of prostate cancer-related death were 18% and 15%, respectively, for intermittent and continuous androgen suppression. http://www.renalandurologynews.com/intermittent-and-continuous-adt-offer-similar-survival/article/257775/ Thu, 06 Sep 2012 15:46:03 GMT The estimated seven-year cumulative rates of prostate cancer-related death were 18% and 15%, respectively, for intermittent and continuous androgen suppression. RUN Phase 2 trial shows benefit in men with recurrent prostate cancer. http://www.renalandurologynews.com/pomegranate-extract-found-to-increase-psa-doubling-time/article/247130/ Mon, 25 Jun 2012 12:00:00 GMT Phase 2 trial shows benefit in men with recurrent prostate cancer. RUN Long-term PSA relapse-free survival after radical prostatectomy (RP) and pelvic lymph node dissection (PLND) is possible in a subset of patients with low volume nodal metastases, a researcher reported at the American Urological Association 2012 annual meeting. http://www.renalandurologynews.com/cure-possible-despite-positive-lymph-nodes/article/242000/ Mon, 21 May 2012 15:30:00 GMT Long-term PSA relapse-free survival after radical prostatectomy (RP) and pelvic lymph node dissection (PLND) is possible in a subset of patients with low volume nodal metastases, a researcher reported at the American Urological Association 2012 annual meeting. RUN PSA-based screening significantly decreases the risk of dying from prostate cancer (PCa), according to updated results of a large European study. http://www.renalandurologynews.com/psa-screening-lowers-prostate-cancer-mortality/article/232317/ Fri, 16 Mar 2012 16:05:08 GMT PSA-based screening significantly decreases the risk of dying from prostate cancer (PCa), according to updated results of a large European study. RUN